Age-related IGF-1 decline permits a redox-sensitive transcriptional shift that directs hematopoiesis toward a CCR2myeloid fate.
Key claim: Age-related decline in bone marrow IGF-1 releases an oxidative stress/NF-κB/IRF8 transcriptional cascade that redirects hematopoietic stem cells onto a CCR2+ myeloid fate trajectory, driving myeloid-biased hematopoiesis and age-associated immunosuppression.
Abstract
Aging reshapes hematopoiesis toward myelopoiesis, particularly increased output of classical monocytes, contributing to immunosenescence. However, the underlying mechanisms remain unclear. Here, we identify that aging drives hematopoietic stem cells (HSCs) to progressively commit to a CCR2monocyte fate along a defined lineage trajectory, which is executed through a redox-sensitive transcriptional cascade. We find that the age-related decline in bone marrow IGF-1 is the upstream niche signal that releases suppression of the oxidative stress/NF-κB/IRF8 axis, allowing this cascade to redirect early progenitors toward a CCR2myeloid-primed fate. Functional assays confirm that cells following this CCR2trajectory drive myeloid-biased hematopoiesis and directly contribute to age-associated immunosuppression. Our work delineates a hierarchical pathway from niche decay to lineage redirection, establishing the CCR2fate trajectory as a key driver of immunosenescence and a potential therapeutic target.
Why this matters
Age-related IGF-1 decline has been discussed mostly as a systemic pro-longevity endocrine shift; this work reassigns part of that decline to the bone-marrow microenvironment and links it, via a defined redox/NF-κB/IRF8 cascade, to a CCR2+ myeloid HSC fate trajectory that could underpin age-associated immunosuppression. It slots into the growing map of upstream drivers of myeloid-biased hematopoiesis and immunosenescence (BIRC6, Lamtor5, NAD, B-cell tolerance), and creates tension with the pure ‘low IGF-1 is protective’ framing by identifying a compartment where IGF-1 loss is causally harmful. Evidence is preclinical only; no human data on the CCR2+ trajectory or interventions targeting it.